CA-HAI-SOLUTIONS
22.5.2023 12:01:33 CEST | Business Wire | Press release
Intellego Technologies and HAI Solutions are proud to announce a strategic partnership that is designed to improve the quality and safety of intravenous (IV) vascular access. The partnership combines Intellego's patented ultraviolet-sensitive ink as an indicator component in HAI Solutions' QIKcap™ technology to offer visible and verifiable IV port protection and provide confidence that the needle-free connector has been disinfected.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005235/en/
The QIKcap (TM) disposable IV luer access cap with Intellego’s chromatic ink changes from yellow to pink, providing visible indication that a sufficient dose of germicidal energy has been delivered by HAI Solutions QIKcap (TM) handheld UV-C disinfection device. (Photo: Business Wire)
The QIKcap Disinfection Device™ is a patented, handheld UV-C tool that is designed to irradiate the surface of an intravenous connector and intravenous access points to prevent microbial ingress. The specialized luer cap, known as QIKcap™, incorporates Intellego’s proprietary ink. When the QIKcap is irradiated with the UV-C handheld device, the cap changes color from yellow to pink, providing visible indication that a sufficient dose of germicidal energy has been delivered in as little as one second.
The development of the QIKcap Disinfection Device and QIKcap is designed to address the continued risk of bloodstream infections (BSI) and hospital onset bacteremia (HOB), which is any positive blood culture obtained 48 hours after admission. In the 2023 Hospital Safety Grade data that was released on May 3, 2023 by The Leapfrog Group, healthcare-associated infections (HAIs) spiked to a 5-year high in U.S. hospitals during the COVID-19 pandemic and remain high. The report noted that the average CLABSI standard infection ratio increased by 60%. HAIs including Methicillin-resistant Staphylococcus aureus (MRSA), central line bloodstream infections (CLABSI) and catheter-associated urinary tract infections (CAUTI) increase the length of hospitalization stays, add to costs and are the leading causes of death in the U.S.
This novel use of Intellego’s photochromic ink as an ingredient in a medical device is a first for the Swedish company that is best known for its product line, UVC Dosimeters. Used by OEMs, in academic research and in healthcare facilities around the world, UVC Dosimeters are the most trusted and reliable single-use UV indicators cards that provide visible measurement of germicidal ultraviolet energy delivered to surfaces.
According to Claes Lindahl, CEO of Intellego Technologies, “We are excited about the opportunity to expand the application of our proprietary ink technology in new and innovative ways to provide visible evidence of successful UV irradiation. Our partnership with HAI Solutions demonstrates our commitment to life-saving technologies and promoting the safety, efficacy and efficiency of ultraviolet disinfection applications.”
"We are thrilled to announce our new strategic partnership with Intellego Technologies,” said Nicholas Perrenoud, CEO of HAI Solutions. “By working together, we will be able to leverage our respective resources and capabilities to drive innovation, create new opportunities, and deliver even greater value to our stakeholders. We look forward to a successful and mutually beneficial partnership with Intellego."
About Intellego Technologies
Intellego Technologies is a research and development company, headquartered in Solna, Sweden. Founded in 2011, Intellego has grown to become the global leader in colorimetric indicators that are utilized worldwide to visually validate the dose of ultraviolet irradiation delivered to surfaces. Through its patented photochromic ink technology, Intellego manufactures standard and customized indicators that make the benefits of germicidal ultraviolet light visible and promotes the safe, effective and efficient use of UV applications. Intellego’s products support better outcomes with ultraviolet devices in healthcare, food and beverage manufacturing, environmental services, and more. For more information, visit Intellego-Technologies.com and UVCdosimeters.com.
About HAI Solutions
Based in Santa Barbara, CA, HAI Solutions is developing a novel and diverse platform of innovative intravenous therapy solutions targeting IV contamination which occurs in challenging medical segments like the Operating Room, Intensive Care Unit and Emergency Room. Founded in 2015, HAI Solutions believes in protecting every patient by advancing clinical care across the healthcare spectrum. For more information, please visit www.HAI-Solutions.com or Twitter @HAISolutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005235/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
UAE Opens 15th UN Congress on Crime Prevention and Criminal Justice and Launches Pledge4Justice with First Pledge of Up to USD 5 Million26.9.2026 22:51:00 CEST | Press release
The 15th United Nations Congress on Crime Prevention and Criminal Justice – Abu Dhabi 2026 kicked off today at ADNEC Centre Abu Dhabi. Set to run until 1 October, the Congress attracts representatives from over 97 countries, including over 32 ministers of justice and interior ministers, alongside senior officials, judges, prosecutors, experts, and youth from around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260926005703/en/ UAE Opens 15th UN Congress on Crime Prevention and Criminal Justice and Launches Pledge4Justice with First Pledge of Up to USD 5 Million (Photo: AETOSWire) The opening session witnessed the adoption of the Abu Dhabi Declaration, which serves as the Congress's principal political and strategic outcome document and will guide international priorities and cooperation in crime prevention, criminal justice and the rule of law over the next five years. The Declaration is structured around four pi
Future Health Convenes Global Health Leaders at UNGA to Advance Health System Transformation at Scale26.9.2026 17:21:00 CEST | Press release
High-level dialogue explored how predictive and preventive health systems can deliver better health outcomes worldwide. Ministers, senior government representatives, and health leaders from 15 countries shared approaches to building health systems that predict risk, prevent disease, and support earlier intervention at population scale. Participants identified population-level data, financing, and delivery capacity as essential to turning earlier insight into action. Trust, community reach, and inclusive design were recognised as critical to ensuring that earlier insight and intervention are delivered effectively and equitably Future Health – A Global Initiative by Abu Dhabi convened Ministers, senior government representatives, and global health leaders in New York on the sidelines of the 81st Session of the United Nations General Assembly (UNGA 81). The high-level dialogue set out practical priorities for moving health systems from reactive treatment towards prediction, prevention, an
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 01:00:00 CEST | Press release
-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for pe
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 21:19:00 CEST | Press release
The offtake agreement connects Digital Reef’s 3.3 GW data centre pipeline with environmental assets from more than 30 million hectares of Amazon rainforest across South America, where Oreasoc Agriculture works directly on the ground alongside local communities to develop sustainable economies and safeguard their territories. Xange.com’s digital MRV technology monitors both the data centres and the rainforest. At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where D
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 15:00:00 CEST | Press release
Planned acquisition strengthens NetApp's position in the rapidly growing AI infrastructure market by bringing differentiated metadata innovation and parallel file architecture designed for AI NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata fr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom